Lannett announced that the FDA has completed its review of the Investigational New Drug Application for biosimilar insulin glargine. Lannett plans to complete the clinical trials by early 2023, with a potential launch in early 2024.
Pearce IP welcomes Julie Ballance, Lawyer, Attorney and Notary to the Executive team
Pearce IP is pleased to announce the promotion of Julie Ballance, Patent Attorney, Lawyer and Notary to Executive. Julie joined Pearce IP in...